Clinical Trials Logo

Recurrent Adult Brain Neoplasm clinical trials

View clinical trials related to Recurrent Adult Brain Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02101905 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Start date: March 13, 2014
Phase: Phase 1
Study type: Interventional

This pilot phase I clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01817751 Active, not recruiting - Glioblastoma Clinical Trials

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Start date: April 11, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.

NCT ID: NCT00823797 Active, not recruiting - Adult Glioblastoma Clinical Trials

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00268385 Active, not recruiting - Adult Glioblastoma Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Start date: December 16, 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.